Study

n

Baseline

Follow-up

Outcome

NYHA

EF (%)

LV size

NYHA

EF (%)

LV size

EF change (%)

LV size reduction

Hospital mortality (%)

Event free survival (%)

Actuarial survival (%)

Period (years)

Athanasuleas 2001 (RESTORE Study)

439

N/A

29

LVESVI 109 mL/m²

N/A

39

LVESVI 69 mL/m²

10

LVESVI 40 mL/m² (37% of baseline)

6.6

85

89.2

1.5

Di Donato 2001

245

N/A

35

LVESVI 112 mL/m²

N/A

48

LVESVI 46 mL/m²

13

LVESVI 66 mL/m² (59% of baseline)

8.1

98

89.9

1

95.8

87.7

2

82.1

74

3

Mickleborough 2004

285

III & IV (83%)

24

LVESVI 97 mL/m²

III & IV (34%)

34

LVESVI 65 mL/m²

10

LVESVI 32 mL/m² (33% of baseline)

2.8

N/A

92

1

82

5

62

10

O’Neill 2006

220

III & IV (66%)

22

LVESVI 120 mL/m²

III & IV (15%)

32

LVESVI 77 mL/m²

10

LVESVI 43 mL/m² (36% of baseline)

1

N/A

92

1

90

3

80

5

Menicanti 2007

488

2.7

33

LVESV 145ml

1.6

40

LVESV 40ml

7

LVESV 105ml (72% of baseline)

4.9

N/A

63

10

Jones 2009 (STICH Trial)

501

III & IV (48%)

28

LVESVI 83 mL/m²

III & IV (15%)

N/A

LVESVI 67 mL/m²

N/A

LVESVI 16 mL/m² (19% of baseline)

5.2

42

72

4